Cargando…

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

BACKGROUND: Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS. METHODS: We conducted a single-arm, open-label, multicentre phase II study to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cassier, P A, Lefranc, A, Y Amela, E, Chevreau, C, Bui, B N, Lecesne, A, Ray-Coquard, I, Chabaud, S, Penel, N, Berge, Y, Dômont, J, Italiano, A, Duffaud, F, Cadore, A-C, Polivka, V, Blay, J-Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749588/ https://www.ncbi.nlm.nih.gov/pubmed/23922114 http://dx.doi.org/10.1038/bjc.2013.442

Ejemplares similares

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome
por: Rochefort, Pauline, et al.
Publicado: (2017)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
por: Penel, N, et al.
Publicado: (2011)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Molecular Mechanisms of Kaposi Sarcoma Development
por: Karabajakian, Andy, et al.
Publicado: (2022)

Determinants of the access to remote specialised services provided by national sarcoma reference centres
por: Fayet, Yohan, et al.
Publicado: (2021)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
por: Patrikidou, Anna, et al.
Publicado: (2020)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study()
por: Mirjolet, C., et al.
Publicado: (2019)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
por: Brahmi, Mehdi, et al.
Publicado: (2022)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
por: Nassif, E.F., et al.
Publicado: (2022)

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
por: Le Cesne, A., et al.
Publicado: (2023)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Geographical Accessibility of the Sarcoma Referral Networks in France. Intermediate Results from the IGéAS Research Program
por: Fayet, Yohan, et al.
Publicado: (2018)

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
por: Huynh, Thanh-Khoa, et al.
Publicado: (2014)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
por: Harttrampf, Anne Catherine, et al.
Publicado: (2021)

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol
por: Lacourt, Aude, et al.
Publicado: (2019)

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
por: Blay, J.-Y., et al.
Publicado: (2023)

No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome?
por: Fayet, Yohan, et al.
Publicado: (2022)

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
por: Giraudet, Anne-Laure, et al.
Publicado: (2018)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

Metabolic landscapes in sarcomas
por: Miallot, Richard, et al.
Publicado: (2021)

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
por: Zhang, A Y, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kpcgqhebvnqit7cpmhal8sm9a3